Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Long-Term Investments (2020 - 2021)

Beam Therapeutics (BEAM) has disclosed Long-Term Investments for 2 consecutive years, with $24.5 million as the latest value for Q3 2021.

  • On a quarterly basis, Long-Term Investments changed N/A to $24.5 million in Q3 2021 year-over-year; TTM through Sep 2021 was $24.5 million, a N/A change, with the full-year FY2020 number at $2.6 million, changed N/A from a year prior.
  • Long-Term Investments was $24.5 million for Q3 2021 at Beam Therapeutics, down from $29.4 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $29.4 million in Q2 2021 to a low of $2.6 million in Q4 2020.